CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
Recombinant methionyl human leptindrug
Likely dose
Recombinant methionyl human leptin 0.04 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00657605
NCT00657605Phase 2Completed
CompareCT.gov

Effects of Human Leptin Replacement

University of Miami·interventional·Posted Apr 14, 2008·Updated Feb 13, 2020

In Brief

A Phase 2 clinical trial evaluating Recombinant methionyl human leptin for Obesity and 2 related conditions. Completed, enrolled 3 participants across 1 site.

Detailed Summary

This study will test the hypothesis that leptin contributes to the regulation of the dynamics of human endocrine function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Metabolic Syndrome, Diabetes
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 14, 2008
Enrollment StartJun 1, 2001
Primary CompletionMay 4, 2010
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 18.2 years ago

Interventions

Recombinant methionyl human leptindrug

Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.